Immunological Medicine最新文献_第6页

An in silico approach for prediction of B cell and T cell epitope candidates against Chikungunya virus. 预测基孔肯雅病毒B细胞和T细胞候选表位的计算机方法。

IF 4.4

Immunological Medicine Pub Date : 2023-12-01 Epub Date: 2023-04-20 DOI: 10.1080/25785826.2023.2202038

Amrit Venkatesan, Usha Chouhan, Sunil Kumar Suryawanshi, Jyoti Kant Choudhari

引用次数: 0

Involvement of the complement system in immune thrombocytopenia: review of the literature. 补体系统在免疫性血小板减少症中的作用:文献综述。

IF 4.4

Immunological Medicine Pub Date : 2023-12-01 Epub Date: 2023-05-26 DOI: 10.1080/25785826.2023.2213976

Risa Shindo, Ryohei Abe, Kenji Oku, Tomoki Tanaka, Yu Matsueda, Tatsuhiko Wada, Yoshiyuki Arinuma, Sumiaki Tanaka, Tatsuyoshi Ikenoue, Yoshitaka Miyakawa, Kunihiro Yamaoka

{"title":"Involvement of the complement system in immune thrombocytopenia: review of the literature.","authors":"Risa Shindo, Ryohei Abe, Kenji Oku, Tomoki Tanaka, Yu Matsueda, Tatsuhiko Wada, Yoshiyuki Arinuma, Sumiaki Tanaka, Tatsuyoshi Ikenoue, Yoshitaka Miyakawa, Kunihiro Yamaoka","doi":"10.1080/25785826.2023.2213976","DOIUrl":"10.1080/25785826.2023.2213976","url":null,"abstract":"Immune thrombocytopenia (ITP) is a thrombocytopenic condition induced by autoimmune mechanisms and includes secondary ITP with underlying diseases such as connective tissue diseases (CTD). In recent years, it has been elucidated that the subsets of the ITP are associated with complement abnormalities but much remains unclear. To perform a literature review and identify the characteristics of complement abnormalities in ITP. PUBMED was used to collect the literature published up to June 2022 related to ITP and complement abnormalities. Primary and secondary ITP (CTD-related) were examined. Out of the collected articles, 17 were extracted. Eight articles were related to primary ITP (pITP) and 9 to CTD-related ITP. Analysis of the literature revealed that the ITP severity was inversely correlated with serum C3, C4 levels in both ITP subgroups. In pITP, a wide range of complement abnormalities was reported, including abnormalities of initial proteins, complement regulatory proteins, or the end products. In CTD-related ITP, reported complement abnormalities were limited to the initial proteins. Activation of the early complement system, mainly through activation of C3 and its precursor protein C4, was reported for both ITPs. On the other hand, more extensive complement activation has been reported in pITP.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9524030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Association of IL-17 serum levels with clinical findings and systemic lupus erythematosus disease activity index. 血清IL-17水平与临床表现和系统性红斑狼疮疾病活动指数的关系

IF 4.4

Immunological Medicine Pub Date : 2023-12-01 Epub Date: 2023-04-19 DOI: 10.1080/25785826.2023.2202050

Faegheh Ebrahimi Chaharom, Ali Asghar Ebrahimi, Faroogh Feghhi Koochebagh, Zohreh Babalou, Morteza Ghojazadeh, Leili Aghebati Maleki, Nader D Nader

{"title":"Association of IL-17 serum levels with clinical findings and systemic lupus erythematosus disease activity index.","authors":"Faegheh Ebrahimi Chaharom, Ali Asghar Ebrahimi, Faroogh Feghhi Koochebagh, Zohreh Babalou, Morteza Ghojazadeh, Leili Aghebati Maleki, Nader D Nader","doi":"10.1080/25785826.2023.2202050","DOIUrl":"10.1080/25785826.2023.2202050","url":null,"abstract":"The current study aims to investigate the relationship betweSen serum IL-17 (IL-17) levels and systemic lupus erythematosus disease activity index (SLE-DAEI) in systemic lupus erythematosus (SLE) patients. In this case-control study, 36 patients with SLE and 40 healthy individuals matched for age and sex were included as the control group. The study measured serum IL-17 in both groups. The correlation between serum IL-17 with disease activity (as per SLE-DAI) and organ involvement in SLE patients. The case group in this study consisted of 4 males and 32 females with a mean age of 35 (17-54) years old, and the control group included six males and 34 females with a mean age of 37 (25-53) years old (p = .35). Serum IL-17 was higher in the cases than in the controls (536 pg/mL vs. 110 pg/mL; p < .001). There was a positive correlation between the serum levels of IL-17 and disease activity index (p < .001, rho = 0.93) among cases. Additionally, the serum levels of IL-17 were higher in patients with renal (p = .003) or central nervous system involvement (p < .001) than in patients without such involvement. Serum Il-17 is associated with SLE, and its serum levels correlate positively with the disease activity and renal and nervous system involvement.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9737384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JAK inhibitors ∼ overview∼. JAK抑制剂∼概览》∼。

IF 4.4

Immunological Medicine Pub Date : 2023-09-01 DOI: 10.1080/25785826.2023.2183594

Hideto Kameda

引用次数: 0

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies. 探讨Janus激酶(JAK)在特应性皮炎中的作用:分子机制和治疗策略的综述。

IF 4.4

Immunological Medicine Pub Date : 2023-09-01 DOI: 10.1080/25785826.2023.2214324

Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima

{"title":"Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies.","authors":"Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima","doi":"10.1080/25785826.2023.2214324","DOIUrl":"https://doi.org/10.1080/25785826.2023.2214324","url":null,"abstract":"Recent studies have demonstrated that Janus kinase (JAK) plays a crucial role in signal transduction by directly affecting various cytokine receptors involved in inflammatory diseases such as atopic dermatitis (AD). Large-scale clinical trials on AD utilizing JAK inhibitors and biologic reagents, such as dupilumab, which targets the IL-4Rα receptor subunit of the Th2 cytokines IL-4 and IL-13, have yielded highly favorable results in comparison to traditional therapies. This indicates that therapeutic strategies based on molecular biology are efficacious in clinical settings. However, in September 2021, the U.S. Food and Drug Administration (FDA) indicated that tofacitinib, a JAK inhibitor, may carry various risks, including severe heart disease. Similar concerns have been raised for other JAK inhibitors, and further safety evaluations are underway. Thus, human biology involving JAKs appeared more complicated than we expected. In this article, we provide an overview of the molecular mechanisms of AD and examine the molecular targeting drugs for AD from the perspective of JAK-related biology.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9919927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment. 了解个别Janus激酶抑制剂在溃疡性结肠炎治疗中的疗效，以供未来在炎症性肠病治疗中定位。

IF 4.4

Immunological Medicine Pub Date : 2023-09-01 Epub Date: 2023-04-10 DOI: 10.1080/25785826.2023.2195522

Hiroshi Nakase

引用次数: 0

Recent progress of JAK inhibitors for hematological disorders. JAK抑制剂治疗血液病的最新进展。

IF 4.4

Immunological Medicine Pub Date : 2023-09-01 Epub Date: 2022-10-28 DOI: 10.1080/25785826.2022.2139317

Keita Kirito

{"title":"Recent progress of JAK inhibitors for hematological disorders.","authors":"Keita Kirito","doi":"10.1080/25785826.2022.2139317","DOIUrl":"10.1080/25785826.2022.2139317","url":null,"abstract":"Abstract JAK inhibitors are important therapeutic options for hematological disorders, especially myeloproliferative neoplasms. Ruxolitinib, the first JAK inhibitor approved for clinical use, improves splenomegaly and ameliorates constitutional symptoms in both myelofibrosis and polycythemia vera patients. Ruxolitinib is also useful for controlling hematocrit levels in polycythemia vera patients who were inadequately controlled by conventional therapies. Furthermore, pretransplantation use of ruxolitinib may improve the outcome of allo-hematopoietic stem cell transplantation in myelofibrosis. In contrast to these clinical merits, evidence of the disease-modifying action of ruxolitinib, i.e., reduction of malignant clones or improvement of bone marrow pathological findings, is limited, and many myelofibrosis patients discontinued ruxolitinib due to adverse events or disease progression. To overcome these limitations of ruxolitinib, several new types of JAK inhibitors have been developed. Among them, fedratinib was proven to provide clinical merits even in patients who were resistant or intolerant to ruxolitinib. Pacritinib and momelotinib have shown merits for myelofibrosis patients with thrombocytopenia or anemia, respectively. In addition to treatment for myeloproliferative neoplasms, recent studies have demonstrated that JAK inhibitors are novel and attractive therapeutic options for corticosteroid-refractory acute as well as chronic graft versus host disease.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9953916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

JAK inhibitors in rheumatology. 风湿病抑制剂。

IF 4.4

Immunological Medicine Pub Date : 2023-09-01 Epub Date: 2023-02-06 DOI: 10.1080/25785826.2023.2172808

Kunihiro Yamaoka, Kenji Oku

引用次数: 3

Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination. sars - cov - 2mrna疫苗接种后伴噬淋巴组织细胞增多的补体性荨麻疹血管炎病例。

IF 4.4

Immunological Medicine Pub Date : 2023-06-01 DOI: 10.1080/25785826.2023.2193286

Narumichi Iwamura, Katsumi Eguchi, Tomohiro Koga, Kanako Tsutsumi, Takeshi Araki, Toshiyuki Aramaki, Ayuko Takatani, Kaoru Terada, Yukitaka Ueki

{"title":"Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination.","authors":"Narumichi Iwamura, Katsumi Eguchi, Tomohiro Koga, Kanako Tsutsumi, Takeshi Araki, Toshiyuki Aramaki, Ayuko Takatani, Kaoru Terada, Yukitaka Ueki","doi":"10.1080/25785826.2023.2193286","DOIUrl":"https://doi.org/10.1080/25785826.2023.2193286","url":null,"abstract":"A 61-year-old man with no previous record of autoimmune disease developed fever, polyarthralgia, purpura, and urticaria-like rash 2 weeks after the first dose of the Moderna mRNA-1273 vaccine, and symptoms deteriorated following the second dose. He presented reduced erythrocyte and platelet counts, hyperferritinemia, high sIL-2R levels, and severe hypocomplementemia. We diagnosed hypocomplementemic urticarial vasculitis (HUVS), and his symptoms as well as laboratory findings improved following treatment with mPSL 1000 mg/day for 3 days and PSL 40 mg/day. Twelve weeks following treatment initiation, the patient relapsed with fever, sore throat, pancytopenia, and hyperferritinemia when the PSL dose was reduced to 12.5 mg/day. Bone marrow biopsy and MRI presented fatty marrow and hemophagocytosis. The patient's blood cells started recovering using ATG + CsA + EPAG therapy for hemophagocytic lymphohistiocytosis (HLH). This is the first case report of HUVS and HLH following SARS-CoV-2 mRNA vaccination. It is presumed that SARS-CoV-2 mRNA vaccine can induce the excessive production of certain types of cytokines, such as TNF-α, IL-1, IL-4, IL-5, IL-6, and IL-17 as a consequence of IL-6 Amplification (IL-6 Amp). SARS-CoV-2 mRNA-vaccines can cause disruption of immune homeostasis in healthy individuals. An extremely rare disease of HUVS complicated by HLH can be developed as a consequence.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The association between PD-1 gene polymorphisms and susceptibility to multiple sclerosis. PD-1基因多态性与多发性硬化易感性之间的关系。

IF 4.4

Immunological Medicine Pub Date : 2023-06-01 DOI: 10.1080/25785826.2022.2137967

Nasrin Hassani, Arash Salmaninejad, Saeed Aslani, Eskandar Kamali-Sarvestani, Mahmood Vessal

引用次数: 2